The Effects of Dietary Supplements on Glycemic Control, Body Composition and Hepatic Fat Content in People With Prediabetes
Launched by MEDICAL UNIVERSITY OF VIENNA · May 26, 2024
Trial Information
Current as of February 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how three different dietary supplements may affect blood sugar control, body fat, and liver fat in people who have prediabetes. Prediabetes means that your blood sugar levels are higher than normal but not high enough to be diagnosed as diabetes. The study will last for three months, during which participants will either receive one of the dietary supplements or a placebo (a harmless pill that has no active ingredients). Researchers will conduct blood tests to check various health markers and will also measure liver fat content and body composition. Additionally, participants will fill out questionnaires about their mental well-being, quality of life, eating habits, and exercise routines.
To be eligible for this study, participants must be between 40 and 80 years old, have a specific range of blood sugar levels and body mass index (BMI), and not be on any diabetes medications or have other significant health issues. Women who could become pregnant will need to provide a negative pregnancy test before starting the trial. Those who join the study can expect regular check-ups and tests, and they will be contributing to important research that may help improve health outcomes for people with prediabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • willingness and ability to provide written informed consent and comply with all study requirements,
- • age between 40 and 80 years
- • prediabetes with a HbA1c level between 5,7-6,4%
- • no antidiabetic treatment prior to the inclusion in the study
- • BMI between 25 and 35 kg/m2
- • fasting glucose of 100-125mg/dl
- • in the case of women of childbearing potential, providing a negative pregnancy test at inclusion and once a month until the end of the study
- Exclusion Criteria:
- • failure to provide written informed consent and/or failure to comply with the study requirements
- • age \<40 years
- • HbA1c outside of the set range
- • significant impairments of hepatic and/or renal function
- • clinically significant abnormalities in medical history, routine laboratory screening, or in physical examination
- • allergies against any of the components of the dietary supplements or the placebo
- • type 1 diabetes mellitus, latent autoimmune diabetes in adults, maturity-onset diabetes of the young, gestational diabetes
- • pregnancy, lactation
- • concurrent treatment with any antidiabetic drug
- • concurrent treatment with drugs/dietary supplements that have proven interactions with dietary supplements included in our study
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0